| Q90125534 | A long acting nanoformulated lamivudine ProTide |
| Q89689518 | Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077 |
| Q40255060 | Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States |
| Q49384599 | Are Anal Sex Roles Associated with Preferences for Pre-Exposure Prophylaxis Administration Modalities Among Men Who Have Sex with Men? |
| Q89687189 | Cognitive testing of an instrument to evaluate acceptability and use of pre-exposure prophylaxis products among women |
| Q91438525 | Contemporary Drug-Drug Interactions in HIV Treatment |
| Q50051618 | Creation of a long-acting nanoformulated dolutegravir |
| Q92151655 | Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa |
| Q47377243 | Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. |
| Q90651991 | Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment |
| Q52642470 | Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. |
| Q33848307 | HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial |
| Q64069080 | HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey |
| Q90412714 | HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Preexposure Prophylaxis During Pregnancy |
| Q56992437 | Harnessing nanostructured systems for improved treatment and prevention of HIV disease |
| Q89935357 | Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review |
| Q48342302 | Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence |
| Q47586914 | Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1. |
| Q93001322 | Interest of Youth Living With HIV in Long-Acting Antiretrovirals |
| Q47909110 | Investigational HIV integrase inhibitors in phase I and phase II clinical trials |
| Q42798295 | Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study |
| Q91899040 | Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities |
| Q56794667 | Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study |
| Q36262152 | Long-acting slow effective release antiretroviral therapy |
| Q48147782 | Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. |
| Q90124787 | Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK |
| Q47095093 | Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution |
| Q64356851 | Open-source discovery of chemical leads for next-generation chemoprotective antimalarials |
| Q38807176 | Past, Present, and Future Drug Delivery Systems for Antiretrovirals |
| Q98292337 | Pharmaceutical Approaches to HIV Treatment and Prevention |
| Q58551570 | Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor |
| Q47142890 | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| Q56911248 | Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland |
| Q28076466 | Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy |
| Q89562625 | ProTide generated long-acting abacavir nanoformulations |
| Q46442521 | Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study |
| Q54231340 | Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. |
| Q40186272 | Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study |
| Q38750666 | Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy |
| Q59354852 | Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis |
| Q38615185 | Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis |